Biomarkers

Published by: RI Technologies

Published: Jan. 1, 2008 - 221 Pages

Table of Contents

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

1. Introduction

Biomarkers

Segmentation of Biomarkers

Exhibit 1: Segmentation of Global Biomarkers Market By Discovery Technology (Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other) and Therapeutic Area (Oncology, Cardiology, Neurology and Other)

2. Global Market Analysis

Exhibit 2: Biomarkers (2005-2012) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Therapeutic Area Analysis by Geographic Region

Oncology

Exhibit 3: Biomarkers in Oncology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada andRest of World in US$ Million (Graphical Representation Included)

Exhibit 4: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World

Cardiology

Exhibit 5: Biomarkers in Cardiology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada andRest of World in US$ Million (Graphical Representation Included)

Exhibit 6: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)

Neurology

Exhibit 7: Biomarkers in Neurology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada andRest of World in US$ Million (Graphical Representation Included)

Exhibit 8: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World

Other

Exhibit 9: Biomarkers in Other Therapeutics (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 10: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World

Biomarker Discovery Technology Analysis by Geographic Region

Imaging

Exhibit 11: Imaging Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 12: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)

Genomics

Exhibit 13: Genomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million(Graphical Representation Included)

Exhibit 14: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World(Graphical Representation Included)

Proteomics

Exhibit 15: Proteomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 16: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)

Metabolomics

Exhibit 17: Metabolomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 18: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)

Bioinformatics

Exhibit 19: Bioinformatics for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 20: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World

Other

Exhibit 21: Other Biomarker Discovery Technologies (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 22: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World

Exhibit 23: List of Major Global Companies

3. Regional Market Analysis

North America

Exhibit 24: Biomarkers (2005-2012) - North American Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Major Companies in North America

Affymetrix, Inc. (USA)

Agilent Technologies, Inc. (USA)

Applied Biosystems Group (USA)

AVIVA Biosciences Corporation (USA)

Beckman Coulter, Inc. (USA)

BG Medicine, Inc. (USA)

BioForce Nanosciences, Inc. (USA)

BioMarker Pharmaceuticals, Inc. (USA)

Bristol Myers Squibb Co. (USA)

Bruker Daltonics, Inc. (USA)

Calibrant Biosystems, Inc. (USA)

Caprion Pharmaceuticals, Inc. (Canada)

Celera Genomics Group (USA)

Correlogic Systems, Inc. (USA)

Eli Lilly and Co. (USA)

Fujirebio Diagnostics, Inc. (USA)

Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)

GeneGo, Inc. (USA)

GeneNews Ltd. (Canada)

IBEX Technologies, Inc. (Canada)

Iconix Biosciences, Inc. (USA)

Large Scale Biology Corporation (USA)

Metabolon, Inc. (USA)

Monogram Biosciences, Inc. (USA)

Pathwork Diagnostics (USA)

PerkinElmer, Inc. (USA)

Pfizer, Inc. (USA)

SomaLogic, Inc. (USA)

Thermo Fisher Scientific, Inc. (USA)

Upstream Biosciences, Inc. (Canada)

Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)

Therapeutic Area Analysis by Geographic Region

Oncology

Exhibit 25: Biomarkers in Oncology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)

Exhibit 26: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)

Cardiology

Exhibit 27: Biomarkers in Cardiology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)

Exhibit 28: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)

Neurology

Exhibit 29: Biomarkers in Neurology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)

Exhibit 30: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada

Other (Graphical Representation Included)

Exhibit 31: Biomarkers in Other Therapeutics (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States andCanada in US$ Million (Graphical Representation Included)

Exhibit 32: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)

Biomarker Discovery Technology Analysis by Geographic Region

Imaging

Exhibit 33: Imaging Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States andCanada in US$ Million (Graphical Representation Included)

Exhibit 34: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada (Graphical Representation Included)

Genomics

Exhibit 35: Genomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States andCanada in US$ Million (Graphical Representation Included)

Exhibit 36: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada (Graphical Representation Included)

Proteomics

Exhibit 37: Proteomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)

Exhibit 38: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)

Metabolomics

Exhibit 39: Metabolomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)

Exhibit 40: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)

Bioinformatics

Exhibit 41: Bioinformatics for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States andCanada in US$ Million (Graphical Representation Included)

Exhibit 42: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)

Other

Exhibit 43: Other Biomarker Discovery Technologies (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States andCanada in US$ Million (Graphical Representation Included)

Exhibit 44: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)

Europe

Exhibit 45: Biomarkers (2005-2012) - European Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Major Companies in Europe

ACE BioSciences A/S (Denmark)

Affibody AB (Sweden)

Alphalyse A/S (Denmark)

Bayer AG (Germany)

Biacore International AB (Sweden)

BioSense Laboratories AS (Norway)

Biotrin International (Ireland)

BRAHMS AG (Germany)

Dako A/S (Denmark)

DxS Ltd. (UK)

Epigenomics AG (Germany)

GE Healthcare (UK)

Genedata AG (Switzerland)

GlaxoSmithKline Plc (UK)

MDS Pharma Services (UK)

Nonlinear Dynamics Ltd. (UK)

Novartis AG (Switzerland)

Oy Jurilab Ltd. (Finland)

Proteome Sciences plc (UK)

TheRyte Ltd. (UK)

Therapeutic Area Analysis by Geographic Region

Oncology

Exhibit 46: Biomarkers in Oncology (2005-2012) - European Market Analysis (Current & Future by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 47: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Cardiology

Exhibit 48: Biomarkers in Cardiology (2005-2012) - European Market Analysis (Current & Future by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 49: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Neurology

Exhibit 50: Biomarkers in Neurology (2005-2012) - European Market Analysis (Current & Future by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 51: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Other

Exhibit 52: Biomarkers in Other Therapeutics (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 53: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Biomarker Discovery Technology Analysis by Geographic Region

Imaging

Exhibit 54: Imaging Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 55: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Genomics

Exhibit 56: Genomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 57: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Proteomics

Exhibit 58: Proteomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 59: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Metabolomics

Exhibit 60: Metabolomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden andRest of Europe in US$ Million (Graphical Representation Included)

Exhibit 61: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Bioinformatics

Exhibit 62: Bioinformatics for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 63: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Other

Exhibit 64: Other Biomarker Discovery Technologies (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 65: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Asia-Pacific

Exhibit 66: Biomarkers (2005-2012) -Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Major Companies in Asia-Pacific

Human Metabolome Technologies, Inc. (Japan)

Proteome Systems Ltd. (Australia)

Soiken, Inc. (Japan)

Triesta Sciences, Inc. (India)

Therapeutic Area Analysis by Geographic Region

Oncology

Exhibit 67: Biomarkers in Oncology (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 68: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia andRest of Asia-Pacific (Graphical Representation Included)

Cardiology

Exhibit 69: Biomarkers in Cardiology (2005-2012) - Asia-Pacific Market Analysis (Current & Future by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 70: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia andRest of Asia-Pacific

Neurology

Exhibit 71: Biomarkers in Neurology (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 72: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia andRest of Asia-Pacific (Graphical Representation Included)

Other

Exhibit 73: Biomarkers in Other Therapeutics (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 74: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Biomarker Discovery Technology Analysis by Geographic Region

Imaging

Exhibit 75: Imaging Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 76: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Genomics

Exhibit 77: Genomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 78: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Proteomics

Exhibit 79: Proteomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 80: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Metabolomics

Exhibit 81: Metabolomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 82: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Bioinformatics

Exhibit 83: Bioinformatics for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 84: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Other

Exhibit 85: Other Biomarker Discovery Technologies (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia andRest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 86: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific

Rest of World

Exhibit 87: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Compugen Ltd. (Israel) - A Major Player

III. PRODUCT/TECHNOLOGY RESEARCH

1. Introduction

Biomarkers Growth Trends - Global Markets

Exhibit 88: Global Market for Biomarkers: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Biomarker Groups

Biomarkers of Exposure

Therapeutic Biomarkers

Post Genomic Biomarker-Based Products Market

Exhibit 89: Post Genomic Biomarker Based Products Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)

Laboratory Process of Biomarkers Development

F2-Isoprostances

Reactive Oxygen and Nitrogen Species

Biomarkers Associated with Breath Exhaled

Application of Biomarkers

Medical Sector

Non-Medical Sector

Categorization of Biomarkers

DNA Biomarkers

Mitochondrial DNA

Mitochondrion Transformations Lead to Cancer

RNA Biomarkers

Micro RNAs

Gene Biomarkers

Metabolic Biomarkers

Examining Degradation of Anerobic Hydrocarbon with Metabolic Biomarkers

Cell Biomarkers

Global Market for Cell Based Therapeutics

Exhibit 90: Cell Based Therapeutics Market (2005-2012) - Global Market Analysis (Current & Future) by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Million (Graphical Representation Included)

Exhibit 91: Cell Based Therapeutics Market (2005-2012) - Percentage Breakdown of Global Market Value by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Millions

Single Nucleotide Polymorphism (SNP)

Protein Biomarkers

Upgrade of Proteins for Biomarkers

Protein Biomarkers with Array Technologies

Proteomic Studies to Enhance Drug Development Process

Biomarkers and Molecular Diagnostics

Systems Biology

Aim of Systems Biology

Omics Technologies based Systems Biology

2. Various Diseases - Role of Biomarkers

Growth Trends - Global Biomarker Therapeutic Areas

Exhibit 92: Global Market for Biomarkers: Major Biomarker Therapeutic Areas (Cardiology, Neurology and Oncology) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Oncology

Growth Trends - Global Market for Biomarkers in Oncology Therapeutics

Exhibit 93: Global Market for Biomarkers in Oncology Therapeutics: Geographic Regions (Asia- Pacific, Europe, Japan, Canada, United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Application of biomarkers in Cancer Treatment

Cancer Biomarkers

Serum Biomarkers

Prostate-Specific Antigen

Other serum biomarkers

Lung Cancer and Biomarkers

Features of Biomarkers for Lung Cancer

Breast and Ovarian Cancer

Colorectal Cancer

Hereditary Nonpolyposis Colorectal Cancer

Mass Spectrometry - An Emerging Tool for Cancer Biomarker Discovery

Role of Chromatography & Mass Spectrometry in Cancer Treatment

Mass Spectrometry to Aid Laboratory Methods

Global Marker for Mass Spectrometry

Exhibit 94: Mass Spectrometry Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)

Cardiology

Growth Trends - Global Market for Biomarkers in Cardiology Therapeutics

Exhibit 95: Global Market for Biomarkers in Cardiology Therapeutics: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Cardiac Biomarkers - An Overview

Renal Insufficiency-Risk of Cardiovascular Disease

Global Market for Cardiovascular Diagnostics

Exhibit 96: Cardiovascular Diagnostics Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)

Neurology

Growth Trends - Global Market for Biomarkers in Neurology Therapeutics

Exhibit 97: Global Market for Biomarkers in Neurology Therapeutics: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Neurodegenerative Diseases

Global Neurodegerative Diseases Market

Exhibit 98: Neurodegerative Diseases Market - Global Estimates and Projections for the

Period 2005-2012 in US$ Million (Graphical Representation Included)

Alzheimer’s

Parkinson’s

Huntington’s

Traumatic Brain Injury

Other

Biomarkers for Detection of Arthritis

Rheumatic Arthritis

Biomarkers in Gynecology

Pre-Eclampsia in Women

Protein Biomarker to Understand the Condition of Pre-Eclampsia

Pre-Eclampsia’s and Oxidative Stress

Role of Biomarkers of Oxidative Stress in Intricate Pregnancies

Premenstrual Dysphoric Disorder

Analysis of Premenstrual Dysphoric Disorder

Premenstrual Syndrome

Biomarkers in Analyzing Oxidative Stress

Biomarkers to Analyze Oxidative Stress in Lung Disorders

Tuberculosis

Detection of Pulmonary Tuberculosis by Biomarkers

Biomarkers for Detection of SARS Disease

Role of Biomarkers in HIV Detection and Analysis

Role of Biomarkers in Malaria Treatment

Stage I

Stage II

Stage III or Key Stage

Ageing Biomarkers

Exhibit 99: Ageing Biomarkers and Their Effect

Biomarkers for Detection of Renal Difficulties Leading To Diabetes Mellitus

Type 1 diabetes

Type -2 diabetes

3. Biomarker Identification Technologies

Growth Trends - Global Biomarker Therapeutic Areas

Exhibit 100: Global Market for Biomarkers: Major Biomarker Discovery Technologies (Bioinformatics, Genomics, Metabolomics, Proteomics and Imaging) Ranked by Projected

CAGR for 2005 through 2012 (Graphical Representation Included)

Imaging Technologies

Imaging in Preclinical Studies

Imaging Clinical Trials-Cancer

Growth Trends - Global Imaging Technologies Market for Biomarkers Discovery

Exhibit 101: Global Market for Imaging Technologies for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Major Imaging Technologies

Computer Tomography (CT)

Magnetic Resonance Imaging (MRI)

Diffusion MRI techniques

Ultrasound or Sonography using MRI

Magnetic Resonance Angiography (MRA)

Magnetic Resonance Spectroscopy (MRS)

Positron Emission Tomography (PET)

Method of Usage

Genomics

Growth Trends - Global Genomics Market for Biomarkers Discovery

Exhibit 102: Global Genomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Proteomics

Growth Trends - Global Proteomics Market for Biomarkers Discovery

Exhibit 103: Global Proteomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

The Key Technologies that are used for Proteomics

Matrix Assisted Laser Desorption Ionization (MALDI)

Metabolomics

Growth Trends - Global Metabolomics Market for Biomarkers Discovery

Exhibit 104: Global Metabolomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

The Crucial Role of Metabolomics in Discovery

Biomarkers Discovery and Validation through Urinary Proteomics

Urinary Exosomes

Bioinformatics

Growth Trends - Global Bioinformatics Market for Biomarkers Discovery

Exhibit 105: Global Bioinformatics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Other

Fluorescent Indicators for Cancer Biomarkers and Neutral Sugars

Identification of Biomarkers by Feature Wrappers

Nanobiotechnology

Biomarkers and Nanoproteins

4. Biomarkers in Drug Discovery/Development

Biomarkers Application in Pharma Industry

Nuclear Magnetic Resonance Techniques

Mass Spectrometry Techniques to Aid the Study of Proteomics

Top Down

Bottoms Up

Genomics Techniques

Metabolomics Techniques

Devising and Monitoring of Biological Structure

Devising of Sensors

Data Base Management and Visualization Tools for Bioinformatics

Varieties of Micro Arrays Employed in Pharmaceutical Sectors

Eco Toxicology Techniques

Why Pharma/Biotech Industry is Keen in Biomarkers?

Application and Benefits of Biomarkers in Drug Development

Verification of Biomarkers Applicability

Biomarkers Application in Clinical Drug Development

Biomarkers Effect on Discovery and Application of a Drug

Drug Safety and Role of Biomarkers

Toxic Biomarkers to Aid Drug Manufacture

Toxicoproteomics

PK/PD Biomarkers in Drug Development

5. Product Trends

Enhanced Treatment for Spondylarthritis with Innovative Biomarkers

A New Diagnostic Marker to Measure Efficiency of Cancer Drug

SINE RNA to Emerge as Biomarker for Tobacco Hazards

Kinetic Biomarker Enhances Drug Development

New Biomarkers to Detect Nephrotoxicity

Biomarkers in Combination with Pharmacogenomics

IV. MARKET DYNAMICS

1. Market Overview

Global Market Analysis

Exhibit 106: Biomarkers (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 107: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada andRest of World (Graphical Representation Included)

2. Market Trends

Biomarkers - An Emerging Trend in Pharma Industry

Biomarkers Becoming Important in Developing Better Drugs

Pharma Companies Investing Huge Amounts in Biomarkers Discovery

What Pharma Companies Looking in Biomarkers?

3. Major Companies in Biomarker Industry

Affibody AB (Sweden)

Affymetrix, Inc. (USA)

Agilent Technologies, Inc. (USA)

Applied Biosystems Group (USA)

AVIVA Biosciences Corporation (USA)

Bayer AG (Germany)

Beckman Coulter, Inc. (USA)

BG Medicine, Inc. (USA)

Biacore International AB (Sweden)

BioForce Nanosciences, Inc. (USA)

BioMarker Pharmaceuticals, Inc. (USA)

BioSense Laboratories AS (Norway)

Biotrin International (Ireland)

BRAHMS AG (Germany)

Bristol Myers Squibb Co. (USA)

Bruker Daltonics, Inc. (USA)

Calibrant Biosystems, Inc. (USA)

Caprion Pharmaceuticals, Inc. (Canada)

Celera Genomics Group (USA)

Compugen Ltd. (Israel)

Correlogic Systems, Inc. (USA)

Dako A/S (Denmark)

Diagnostics Products Corporation (USA)

DxS Ltd. (UK)

Eli Lilly and Co. (USA)

Epigenomics AG (Germany)

Fujirebio Diagnostics, Inc. (USA)

GE Healthcare (UK)

Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)

Genedata AG (Switzerland)

Genego, Inc. (USA)

GeneNews Ltd. (Canada)

Human Metabolome Technologies, Inc. (Japan)

IBEX Technologies, Inc. (Canada)

Iconix Biosciences, Inc. (USA)

Large Scale Biology Corporation (USA)

MDS Pharma Services (UK)

Metabolon, Inc. (USA)

Monogram Biosciences, Inc. (USA)

Nonlinear Dynamics Ltd. (UK)

Novartis AG (Switzerland)

Oy Jurilab Ltd. (Finland)

Pathwork Diagnostics (USA)

PerkinElmer, Inc. (USA)

Pfizer, Inc. (USA)

Proteome Sciences plc (UK)

Proteome Systems Ltd. (Australia)

Soiken, Inc. (Japan)

SomaLogic, Inc. (USA)

Thermo Fisher Scientific, Inc. (USA)

TheRyte Ltd. (UK)

Triesta Sciences, Inc. (India)

Upstream Biosciences, Inc. (Canada)

Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)

4. Major Activities in Biomarker Industry

GlaxoSmithKline Biologicals and OncoMethylome Sciences Collaborate for Developing Personalized Cancer Treatment

Biomarker Discovered by Korean Researchers to Help in Early Detection of Cancer

Singulex’s Biomarker Detection System used in Wyeth’s Research

Proteome Sciences Introduces Tandem Mass Tag that Helps Overcome Biomarker Validation Bottleneck

Celera and Ipsen Enter Research Collaboration Agreement to Develop Pharmacogenomic Tests

Genedata Signs Japanese Research Initiative to Study Metastatic Biomarkers

Upstream Biosciences Introduces New Cheminformatics Program to Develop New Drug Discovery Capabilities

Banyan Biomarkers Starts International Clinical Trials for Detecting Traumatic Brain injury with Biomarkers

Marshfield Clinic’s Warfarin Biomarker Licensed to Osmetech

Siemens Medical Solutions Diagnostics and B•R•A•H•M•S Agree to Develop Procalcitonin (PCT) Assay on Siemens Immunoassay Platforms

Fujirebio Diagnostics Granted Patent for Ovarian Cancer Biomarker

Gene Logic Adopts New Corporate Identity

Celera Completes Acquisition of Atria Genetics, Inc.

Olink Bioscience and Applied Biosystems to Collaborate for Commercializing Biomarker Validation Technology

Strategic Alliance between GE Global Research, GE Healthcare and Eli Lilly to Develop Molecular In-Vitro Diagnostics for Cancer Therapy

BG Medicine Collaborates with Spinal Muscular Atrophy Foundation

Vermillion (formerly Ciphergen) Publishes Protein Biomarker Research for PAD

Upstream Biosciences Acquires Pacific Pharma Technologies Inc.

Ciphergen Adopts New Corporate Identity

Upstream Biosciences Signs Agreement with Analytical Biological Services to Provide Tissue Samples for Biomarker Validation

Genedata Signs Agreement with Fiehn Laboratory for Refiner MS and Analyst Software

Proteome Systems Signs Agreement with BD to Develop Tuberculosis Diagnostics

New Collaboration between Partners HealthCare and Affymetrix for Developing Personalized Medicine at a Faster Pace

Upstream Biosciences Signs Agreement with Genpathway to Further Biomarker Validation Studies

Millipore Acquires Serologicals

Dade Behring Receives Sublicense for using Beckman Counter’s New Cardiac Biomarkers

Monarch Lifesciences Enters into an Agreement with Genego to Provide Pathway Analysis Services using 1-2-3 Workflow

TIBCO Completes Acquisition of Spotfire

Monarch LifeSciences™, the New Identity for INCAPS

Roche Closes BioVeris Acquisition

BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker

BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration

BG Medicine Forms Research Collaboration with M. D. Anderson Cancer Center

Carestream Health Launched (Kodak Health Renamed as Carestream Health)

New Collaboration Agreement between Affymetrix Clinical Services Lab, Agencourt, and NuGEN Technologies for Blood Sample Expression Profiling with GeneChip(R) Microarrays

Boehringer Ingelheim Expands License with GeneGo to Global Scale

Upstream Biosciences Inc. Signs Agreement with NimbleGen Systems Inc. for Biomarker Validation Studies

Compugen Enters into Second Diagnostic Agreement with Biosite

Lipomics and Agilent Technologies Collaborate on Research and Development of Diagnostic Biomarker Assays

Compugen to Collaborate with Teva for Discovery of Novel Biomarkers for Drug Toxicity

Illumina Acquires Complete Stake in Solexa

BG Medicine and Applied Biosystems to Collaborate on Molecular Medicine Research

Epigenomics AG Joins Hands with Centocor Inc. to Discover Biomarkers

Siemens Medical Solutions Acquires Bayer’s Healthcare Diagnostic Division

BD Acquires TriPath

Genetix Acquires Applied Imaging Corp

Bruker Daltonics Expands Biomarker Discovery Collaboration with HealthLinx

Rules-Based Medicine Merges with Multiplex Biosciences

Bio-Rad Acquires Ciphergen’s Life Science Business

Caprion Pharmaceuticals and Vertex Pharmaceuticals Expand Biomarker Discovery Collaboration

Iconix Changes Corporate Identity

Lumera Extends Collaboration with Institute for Systems Biology

Tandem Labs Takes Over PharmaKD

Axela Collaborates with Abnova to Develop Biomarker Panels

Genstruct Extends Agreement GlaxoSmithKline

Epigenomics AG Signs R&D Agreement with Johnson & Johnson

Siemens Acquires Diagnostic Products Corp

PerkinElmer and University of Leicester Sign Research Agreement

Asterand Enters into Partnership with Rubicon

Applied Biosystems Collaborates with SAIC-Frederick

PPD Signs Agreement with PDL BioPharma

ART Acquires Alerion Biomedical

Varian Acquires IonSpec Corp.

BD Takes Over GeneOhm

Cytomyx Partners with OrigGene

Merck Signs Agreement with FoxHollow Technologies

Wyeth Expands Collaboration with Caprion

Compugen Enters into Collaboration with Ortho-Clinical Diagnostics

BioSystems International Signs Agreement with Euroscreen

PPD Takes Over SurroMed

5. Major Product Innovations/Launches in Biomarker Industry

BioServe Introduces ControlMATCH for Improving Biomarker Validation

Metabolon Launches New mVision™ for Biomarker Discovery

New Human-14 Protein Removal System Introduced by Agilent Technologies

New Tools for Biomarker Research from Applied Biosystems and MDS’ Sciex

PerkinElmer Introduces New Assay Development Service for Homogenous ELISA Conversions

Genedata Launches New Expressionist for Enhanced Cross-Omics Technology integration in Biomarker Discovery

Fluidigm Launches Biomark™ System

OXIS Launches New Reagents and Antibodies

OGeS and Oxford University Develop Novel Biomarkers

ART Launches Fenestra™

Agilent Launches Liquid Chromatography (LC) Column

Bruker Daltonics Launches Molecular Imager

Waters Enhances ProteinLynx

Beckman Coulter Upgrades ProteomeLab™

GeneData Launches Expressionist® Pro 3.0

GenoLogics Enhances ProteusLIMS™

Nonlinear Launches Progenesis PG600

Bruker Daltonics Upgrades ClinProt™

PekinElmer Launches BioXPRESSION™

BioGenex Unveils Xmatrx

Waters Introduces MassTrak Clinical Solutions

Bruker Daltonics Launches Clinical Proteomics System

Fujirebio Diagnostics Introduces Blood Test for Mesothelioma

6. Regional Market Analysis

A. The United States

Market Analysis

Exhibit 108: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 109: List of Major Companies in the United States

Analysis by Therapeutic Area

Exhibit 110: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 111: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 112: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 113: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B. Europe

Market Analysis

Exhibit 114: Biomarkers (2005-2012) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 115: List of Major Companies in Europe

Analysis by Geographic Region

Exhibit 116: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 117: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe

Analysis by Therapeutic Area

Exhibit 118: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 119: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 120: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 121: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

European Biomarkers Market By Country

B1. Germany

German Market Analysis

Analysis by Therapeutic Area

Exhibit 122: Biomarkers (2005-2012) - German Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 123: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 124: Biomarkers (2005-2012) - German Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 125: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B2.The United Kingdom

UK Market Analysis

Analysis by Therapeutic Area

Exhibit 126: Biomarkers (2005-2012) - United Kingdom Market Analysis (Current & Future by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 127: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 128: Biomarkers (2005-2012) - United Kingdom Market Analysis (Current & Future by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 129: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B3. Italy

Italian Market Analysis

Analysis by Therapeutic Area

Exhibit 130: Biomarkers (2005-2012) - Italian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 131: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Italian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 132: Biomarkers (2005-2012) - Italian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 133: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Italian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B4. France

French Market Analysis

Analysis by Therapeutic Area

Exhibit 134: Biomarkers (2005-2012) - French Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 135: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 136: Biomarkers (2005-2012) - French Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 137: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B5. Spain

Spanish Market Analysis

Analysis by Therapeutic Area

Exhibit 138: Biomarkers (2005-2012) - Spanish Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 139: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Spanish Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 140: Biomarkers (2005-2012) - Spanish Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other (Graphical Representation Included)

Exhibit 141: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Spanish Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B6. Switzerland

Swiss Market Analysis

Analysis by Therapeutic Area

Exhibit 142: Biomarkers (2005-2012) - Swiss Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 143: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swiss Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 144: Biomarkers (2005-2012) - Swiss Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 145: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swiss Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B7. Belgium

Belgian Market Analysis

Analysis by Therapeutic Area

Exhibit 146: Biomarkers (2005-2012) - Belgian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 147: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 148: Biomarkers (2005-2012) - Belgian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 149: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B8. Sweden

Swedish Market Analysis

Analysis by Therapeutic Area

Exhibit 150: Biomarkers (2005-2012) - Swedish Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 151: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swedish Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 152: Biomarkers (2005-2012) - Swedish Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 153: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swedish Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

B9. Rest of Europe

Rest of Europe Market Analysis

Analysis by Therapeutic Area

Exhibit 154: Biomarkers (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 155: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 156: Biomarkers (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 157: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

C. Japan

Market Analysis

Exhibit 158: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 159: List of Major Companies in Japan

Analysis by Therapeutic Area

Exhibit 160: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 161: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other (Graphical Representation Included)

Analysis by Biomarker Discovery Technology

Exhibit 162: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 163: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

D. Asia-Pacific

Market Analysis

Exhibit 164: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 165: List of Major Companies in Asia-Pacific

Analysis by Geographic Region

Exhibit 166: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)

Exhibit 167: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia andRest of Asia-Pacific (Graphical Representation Included)

Analysis by Therapeutic Area

Exhibit 168: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 169: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 170: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 171: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

Asia-Pacific Biomarkers Market By Country

D1. China

Chinese Market Analysis

Analysis by Therapeutic Area

Exhibit 172: Biomarkers (2005-2012) - Chinese Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 173: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Chinese Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 174: Biomarkers (2005-2012) - Chinese Market Analysis (Current & Future by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 175: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Chinese Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

D2. India

Indian Market Analysis

Analysis by Therapeutic Area

Exhibit 176: Biomarkers (2005-2012) - Indian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 177: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Indian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 178: Biomarkers (2005-2012) - Indian Market Analysis (Current & Future by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 179: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Indian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

D3. Australia

Australian Market Analysis

Analysis by Therapeutic Area

Exhibit 180: Biomarkers (2005-2012) - Australian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 181: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 182: Biomarkers (2005-2012) - Australian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 183: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics

D4. Rest of Asia-Pacific

Rest of Asia-Pacific Market Analysis

Analysis by Therapeutic Area

Exhibit 184: Biomarkers (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 185: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 186: Biomarkers (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 187: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

E. Canada

Market Analysis

Exhibit 188: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 189: List of Major Companies in Canada

Analysis by Therapeutic Area

Exhibit 190: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 191: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Canadian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other(Graphical Representation Included)

Analysis by Biomarker Discovery Technology

Exhibit 192: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 193: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Canadian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other

F. Rest of World

Market Analysis

Exhibit 194: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 195: List of Major Companies in Rest of World

Analysis by Therapeutic Area

Exhibit 196: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)

Exhibit 197: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other

Analysis by Biomarker Discovery Technology

Exhibit 198: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)

Exhibit 199: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics Bioinformatics and Other

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.